SCHEMBL14701262

SCHEMBL14701262

Cn1cc(N2CCN(C(C)(C)C)CC2)cn1

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
SOS1 Q07889 4/20 0.32
MELK Q14680 1/20 0.32
HTR3A P46098 1/20 0.32
LRRK2 Q5S007 4/20 0.32
ACVR1 Q04771 1/20 0.31
CHRM1 P11229 2/20 0.30
GRIN2D O15399 1/20 0.30
GRIN3B O60391 1/20 0.30
CHRM2 P08172 1/20 0.30
OPRM1 P35372 1/20 0.30
GRIN1 Q05586 1/20 0.30
KCNH2 Q12809 1/20 0.30
GRIN2A Q12879 1/20 0.30
GRIN2B Q13224 1/20 0.30
GRIN2C Q14957 1/20 0.30
GRIN3A Q8TCU5 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6883030 0.80 ALDH1A1 (0.46) MELKHTR3AACVR1ALDH1A1
SCHEMBL18107430 0.78 CHKA (0.41) LRRK2ACVR1ALDH1A1
SCHEMBL16546674 0.77 WNT1 (0.36) GSK3BDYRK1ALRRK2ACVR1KCNH2
SCHEMBL18107285 0.76 ROCK2 (0.41) LRRK2ALDH1A1
SCHEMBL28316935 0.75 RET (0.34) GSK3BDYRK1ALRRK2CHRM1ALDH1A1
SCHEMBL6888248 0.74 CHRNA7 (0.52) LRRK2ALDH1A1
SCHEMBL20009006 0.74 KDM4E (0.49) GSK3BDYRK1ASOS1LRRK2ACVR1
SCHEMBL18107206 0.74 CHKA (0.47) MELKACVR1ALDH1A1
SCHEMBL18107278 0.73 LMNA (0.45) LRRK2ALDH1A1
SCHEMBL12065191 0.73 ADRB1 (0.47) HTR3AACVR1CHRM1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507494-B2 Heterocyclic quinolizine derived M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2013-08-13 US disclosed
US-20130040959-A1 Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME LLC 2013-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040959-A1 Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators CHRM1, OPRL1, CHRNA5 GSK3B 1757/4885DYRK1A 1012/4885SOS1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.